---
title: Antibiotics
date: 2024-08-09
tags:
  - medicine/antibiotics
  - teaching
  - share
status: finished
share_link: https://share.note.sx/phl07lrt#m3+7fJ/DzSGBZILBoqvN0puQctK6xych9ZWRA5I/WLw
share_updated: 2024-08-14T17:58:55+08:00
share: true
categories:
  - medicine
  - abx
aliases: abx
---
# Antibiotics  
## 作用機制  
![[../assets/d5cd1072950af118968f9283c66a7d7c_MD5.jpeg|mechanism]]  
  
<!-- more -->  
  
| ANTIBACTERIAL AGENT(S)                                                                                     | MAJOR TARGET           | MECHANISM(S) OF ACTION                                                                                                                                                   | MECHANISM(S) OF RESISTANCE                                                                                                                                                             |  
| ---------------------------------------------------------------------------------------------------------- | ---------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| β-Lactams (penicillins, cephalosporins, monobactams, carbapenems)                                          | Cell-wall synthesis    | Bind cell-wall cross-linking enzymes (PBPs, **transpeptidases**)                                                                                                         | 1. Drug inactivation by β-lactamases<br>    <br>2. Altered PBP targets<br>    <br>3. Reduced diffusion through porin channels<br>    <br>4. Altered iron uptake proteins (cefiderocol) |  
| Glycopeptides and lipoglycopeptides (vancomycin, teicoplanin, telavancin, dalbavancin, oritavancin)        | Cell-wall synthesis    | Block cell wall glycosyltransferases by binding D-Ala-D-Ala stem-peptide terminus<br><br>Teicoplanin, telavancin, dalbavancin, and oritavancin: affect membrane function | 1. Altered D-Ala-D-Ala target (D-Ala-D-Lac)<br>    <br>2. Increased D-Ala-D-Ala target binding at sites distant from cell wall synthesis enzymes                                       |  
| Bacitracin                                                                                                 | Cell-wall synthesis    | Blocks lipid carrier of cell wall precursors                                                                                                                             | Active drug efflux                                                                                                                                                                     |  
| Fosfomycin                                                                                                 | Cell-wall synthesis    | Blocks linkage of stem peptide to NAG by enoyltransferase                                                                                                                | 1. Target enzyme overexpression<br>    <br>2. Drug-modifying enzymes                                                                                                                   |  
| Aminoglycosides (gentamicin, tobramycin, amikacin, plazomicin)                                             | Protein synthesis      | Bind 30S ribosomal subunit<br><br>Block translocation of peptide chain<br><br>Cause misreading of mRNA                                                                   | 1. Drug-modifying enzymes<br>    <br>2. Methylation at ribosome binding site<br>    <br>3. Decreased permeation to target due to active efflux                                         |  
| Tetracyclines (tetracycline, doxycycline, minocycline)                                                     | Protein synthesis      | Bind 30S ribosomal subunit<br><br>Inhibit peptide elongation                                                                                                             | 1. Active drug efflux<br>    <br>2. Ribosomal protection proteins                                                                                                                      |  
| Tigecycline, eravacyclin, omadacycline                                                                     | Protein synthesis      | Same as tetracyclines                                                                                                                                                    | Active drug efflux (pumps different from those affecting tetracyclines)                                                                                                                |  
| Macrolides (erythromycin, clarithromycin, azithromycin) and the ketolide telithromycin                     | Protein synthesis      | Bind 50S ribosomal subunit<br><br>Block peptide chain exit                                                                                                               | 1. Methylation at ribosome binding site<br>    <br>2. Active drug efflux                                                                                                               |  
| Lincosamides (clindamycin)                                                                                 | Protein synthesis      | Bind 50S ribosomal subunit<br><br>Block peptide bond formation                                                                                                           | Methylation at ribosome binding site                                                                                                                                                   |  
| Streptogramins (quinupristin, dalfopristin)                                                                | Protein synthesis      | Same as macrolides                                                                                                                                                       | 1. Same as macrolides<br>    <br>2. Drug-modifying enzymes                                                                                                                             |  
| Chloramphenicol                                                                                            | Protein synthesis      | Binds 50S ribosomal subunit<br><br>Blocks aminoacyl tRNA positioning                                                                                                     | Drug-modifying enzymes                                                                                                                                                                 |  
| Oxazolidinones (linezolid, tedizolid)                                                                      | Protein synthesis      | Bind 50S ribosomal subunit<br><br>Inhibit initiation of peptide synthesis                                                                                                | 1. Altered rRNA binding site<br>    <br>2. Methylation of ribosome binding site                                                                                                        |  
| Pleuromutilins (lefamulin)                                                                                 | Protein synthesis      | Bind 50S ribosomal subunit<br><br>Blocks peptidyl transferase center                                                                                                     | 1. Altered L3 and L4 protein binding site<br>    <br>2. Methylation of ribosome binding site                                                                                           |  
| Mupirocin                                                                                                  | Protein synthesis      | Blocks isoleucyl tRNA synthetase                                                                                                                                         | 1. Acquired resistant tRNA synthetase (drug bypass)<br>    <br>2. Altered native tRNA synthetase target                                                                                |  
| Sulfonamides (sulfadiazine, sulfisoxazole, and sulfamethoxazole)                                           | Folate synthesis       | Inhibit dihydropteroate synthetase                                                                                                                                       | Acquired resistant dihydropteroate synthetase (drug bypass)                                                                                                                            |  
| Trimethoprim                                                                                               | Folate synthesis       | Inhibits dihydrofolate reductase                                                                                                                                         | Acquired resistant dihydrofolate reductase (drug bypass)                                                                                                                               |  
| Quinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin, delafloxacin) | DNA synthesis          | Inhibit DNA gyrase and DNA topoisomerase IV<br><br>Enzyme–DNA–drug complex: blocks DNA replication apparatus                                                             | 1. Altered target(s)<br>    <br>2. Active efflux<br>    <br>3. Protection of target from drug<br>    <br>4. Drug-modifying enzyme (ciprofloxacin)                                      |  
| Rifamycins (rifampin, rifabutin, rifapentine)                                                              | RNA synthesis          | Inhibit RNA polymerase                                                                                                                                                   | Altered target                                                                                                                                                                         |  
| Nitrofurantoin                                                                                             | Nucleic acid synthesis | Reduces reactive drug derivatives that damage DNA                                                                                                                        | Altered drug-activating enzymes                                                                                                                                                        |  
| Metronidazole                                                                                              | Nucleic acid synthesis | Reduces reactive drug derivatives that damage DNA                                                                                                                        | 1. Altered drug-activating enzyme<br>    <br>2. Acquired detoxifying enzymes<br>    <br>3. Active efflux                                                                               |  
| Polymyxins (polymyxin B and polymyxin E [colistin])                                                        | Cell membrane          | Bind LPS and disrupt both outer and cytoplasmic membranes                                                                                                                | Altered cell-membrane charge with reduced drug binding                                                                                                                                 |  
| Daptomycin                                                                                                 | Cell membrane          | Produces membrane channel and membrane leakage                                                                                                                           | Altered cell-membrane charge with reduced drug binding                                                                                                                                 |  
  
### 抗藥性機轉  
![[../assets/be7c385cf6d7376b54c4de4794df94d7_MD5.jpeg|resistance_zh]]  
![[../assets/64e57133364b2f9716df1ac514b4d418_MD5.jpeg|resistance_en]]  
### 藥物動力學  
  
- 藥物動力學：描述藥物在體內的分布情況  
- 藥效動力學：描述藥物作用於病原體的決定因素，並與藥物動力學因素相關  
#### 濃度依賴型抗生素  
這類抗生素多為抑制細菌蛋白質或核酸合成的抗生素，如aminoglycosides、fluoroquinolones，因其殺菌作用與血中濃度呈正比，為達最大之殺菌作用，建議抗生素之Cmax須高於MIC 4倍以上，且因其有抗生素後效應 (Post-antibiotic effect,PAE) 的特性，即便血中藥物濃度在給藥間隔期間內低於MIC，仍可維持一定的抗菌作用。因此採高劑量、延長給藥間隔的方式投予是比較理想的方式，once-daily  
aminoglycoside的給藥模式即以此理念所發展。  
#### 時間依賴型抗生素  
這類抗生素多為beta-lactams類，如penicillin、cephalosporins。對penicillin和cephalosporins而言，血中藥物濃度>MIC的時間越長越能滲透體內組織，建議治療期間的血中濃度有50%以上的時間高於MIC，以達療效最大化、抗生素耐藥性最小化的目標。此類藥品以連續輸注或延長輸注時間的方式給藥，除了可穩定抗生素血中濃  
度的變化、不增加重症患者AKI的發生率外，對整體的醫療照護支出費用也可顯著降低。  
#### 曲線下面積/最低抑菌濃度相關  
如vancomycin，建議血中藥物濃度之曲線下面積 (AUC) 與MIC比值達到400-600  
mg × h/L的目標（假設MIC為1），可確保抗生素療效與安全性。  
### Penetration/Tissue concentration  
  
- 過BBB: penicillin, ampicillin, oxacillin, 3rd-4th cephalosporins, moxifloxacin, vancomycin, chloramphenicol, rifampin, imipenem, meropenem, trimethoprim-sulfamethoxazole  
- Prostatitis/epididymo-orchitis: ceftriaxone, doxycycline, fluoroquinolones, trimethoprim-sulfamethoxazole  
- Endophthalmitis: 3rd cepha, vancomycin, triazoles, L-AMB  
- Intracellular bacteria: lipid soluble agents (e.g. macrolides, quinolones, rifampicin)  
#### Bone penetration for selected antibiotics  
  
| Antibiotic            | Range of mean bone to serum concentration ratios |  
|-----------------------|--------------------------------------------------|  
| Levofloxacin          | 0.36-1.0                                         |  
| Ciprofloxacin         | 0.27-1.2                                         |  
| Moxifloxacin          | 0.33-1.05                                        |  
| Vancomycin            | 0.05-0.67                                        |  
| Linezolid             | 0.2-0.51                                         |  
| Daptomycin            | 1.17                                             |  
| Clindamycin           | 0.21-0.45                                        |  
| Cefazolin             | 0.179                                            |  
| Ceftriaxone           | 0.07-0.17                                        |  
| Cefuroxime            | 0.04-0.55                                        |  
| Rifampin (rifampicin) | 0.08-0.57                                        |  
  
## 抗菌範圍  
![[../assets/7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg|spectrum]]  
[Source](http://charliekuo.com/?p=3114)  
  
### Anfi-fungals  
  
| Organism                | AmB | Fluconazole | Vori | Isavu | Anidulafungin | 5FC |  
| ----------------------- | --- | ----------- | ---- | ----- | ------------- | --- |  
| *Candida albicans*      | ++  | ++          | ++   | ++    | ++            | ++  |  
| *C. parapsilosis*       | ++  | ++          | ++   | ++    | ++            | ++  |  
| *C. tropicalis*         | ++  | +           | ++   | ++    | ++            | ++  |  
| *C. glabrata*           | +   | +           | ++   | ++    | +             | ++  |  
| *C. krusei*             | +   | -           | ++   | ++    | ++            | +   |  
| *Cryptococcus* spp.     | ++  | ++          | ++   | ++    | -             | ++  |  
| *Aspergillus fumigatus* | ++  | -           | ++   | ++    | +             | -   |  
| *A. flavus*             | +-  | -           | ++   | ++    | +             | -   |  
| *A. terreus*            | -   | -           | ++   | ++    | +             | -   |  
| *A. nigger*             | ++  | -           | ++   | -     | +             | -   |  
| Mucorales               | ++  | -           | -    | ++    | -             | -   |  
| *Fusarium spp.*         | +   | -           | +    | +     | -             | -   |  
  
### MDRO  
  
| 抗藥性細菌                 | 可治療藥物（粗體字為首選）                                                                                                                                                              |  
| --------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| Amp-C β-lactamase GNB | cefepime, **carbapenems**, fluoroquinolones, tigecycline                                                                                                                   |  
| ESBL                  | **carbapenems**, (ceftazidime, piperacillin/tazobactam, fluoroquinolone, trimethoprim-sulfamethoxazole, tigecycline, fosfomycin)                                           |  
| MRSA                  | **vancomycin**, teicoplanin, daptomyxin, linezolid, tigecycline, minocycline, ceftaroline, trimethoprim-sulfamethoxazole, clindamycin, doxycycline, fusidic acid, rifampin |  
| PsA                   | pip/tazo, ceftazidime, cefoperazone, cefepime, ceftazidime/avibactam, meropenem, imipenem, doripenem, ciprofloxacin, levofloxacin, aminoglycosides, cefiderocol, aztreonam |  
| MDRAB                 | carbapenem, **sulbactam**, minocycline, cefiderocol, tigecycline, colistin                                                                                                 |  
| CRE                   | ceftazidime/avibactam, cefidericol, aminoglycosides, colistin, tigecycline, aztreonam, fosfomycin                                                                          |  
| VRE                   | **linezolid**, daptomycin, tigecycline, fosfomycin                                                                                                                         |  
| PRSP                  | ceftriaxone, vancomycin, teicoplanin, tigecycline                                                                                                                          |  
  
![[../assets/24eb7434efb4ee8af42bd23d8cd5c0d2_MD5.jpeg|CRGN]]  
### 特殊細菌  
- Enterococcus: **ampicillin**; cephalosporins沒有效  
- Listeria monocytogenes: **ampicillin**; linezolid, trimethoprim-sulfamethoxazole, penicillin, gentamicin  
- Clostridioides difficile: metronidazole, vancomycin, fidaxomicin  
- Pasteurella multocida: **amoxicillin/clavulanic acid**, penicillin, amoxicillin, cefuroxime, levofloxacin, moxifloxacin, doxycycline, trimethoprim-sulfamethoxazole  
- Neisseria gonorrhoeae: **ceftriaxone**  
- Neisseria meningitides: **penicillin**; ceftriaxone  
- Salmonella spp.: **ceftriaxone**, fluoroquinolone  
- Vibrio: tetracyclines, fluoroquinolone, trimethoprim-sulfamethoxazole  
- Stenotrophomonas maltophila: **trimethoprim-sulfamethoxazole**; levofloxacin, minocycline, colistin, cefiderocol  
- Burkholderia pseudomallei: ceftazidime, meropenem, imipenem  
- Legionella: azithromycin or quinolone  
- Treponema pallidum: penicillin; ceftriaxone, doxycycline  
- Mycoplasma pneumoniae: tetracyclines, erythromycin  
- Chlamydia spp.: tetracyclines, azithromycin  
- Anaerobes: **metronidazole**, amp/sulb, pip/tazo, cephamycin, carbapenems, clindamycin, moxifloxacin, tigecycline  
  
### Drugs of choices  
  
| ANTIMICROBIAL(S)                                        | INFECTIONS                                                                                                                                                                                                                                                                                                                                                                                          | COMMON PATHOGENS (% SUSCEPTIBLE); RESISTANCE AS NOTED[^a]                                                                                                                                                       |  
| ------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| Penicillin G                                            | 梅毒；yaws；鉤端螺旋體病；鏈球菌感染；肺炎鏈球菌感染；放線菌病；口腔和牙周感染；流行性腦膜炎及腦膜炎雙球菌血症；草綠色鏈球菌心內膜炎；梭狀芽孢桿菌性肌壞死；破傷風；鼠咬熱；Pasteurella multocida 感染；丹毒（Erysipelothrix rhusiopathiae）                                                                                                                                                                                                                                                   | _Neisseria meningitidis_; viridans streptococci (69%); _Streptococcus pneumoniae_ (97% nonmeningitis; 75% meningitis)                                                                                           |  
| Ampicillin, amoxicillin                                 | Salmonellosis; 急性中耳炎; _Haemophilus influenzae_ 腦膜炎和會厭炎 ; **_Listeria monocytogenes_ 腦膜炎; _Enterococcus faecalis_ UTI**                                                                                                                                                                                                                                                                              | _Escherichia coli_ (51%); _H. influenzae_ (70%); _Salmonella_ spp. (85%)                                                                                                                                        |  
| Nafcillin, oxacillin                                    | **MSSA**菌血症和心內膜炎                                                                                                                                                                                                                                                                                                                                                                                    | _Staphylococcus aureus_ (70%); coagulase-negative staphylococci (50%)                                                                                                                                           |  
| Piperacillin-tazobactam                                 | 腹腔內感染（兼性腸道革蘭氏陰性桿菌和絕對厭氧菌）；混合菌叢引起的感染（吸入性肺炎、糖尿病足潰瘍）；由 Pseudomonas aeruginosa 引起的感染                                                                                                                                                                                                                                                                                                                     | _P. aeruginosa_ (82%)                                                                                                                                                                                           |  
| Cefazolin                                               | E. coli UTI；手術預防；MSSA 菌血症和心內膜炎                                                                                                                                                                                                                                                                                                                                                                      | _E. coli_ (82%)                                                                                                                                                                                                 |  
| Cefoxitin, cefotetan                                    | 腹腔內感染和骨盆炎性疾病                                                                                                                                                                                                                                                                                                                                                                                        | _Bacteroides fragilis_ (60%)[^b]                                                                                                                                                                                |  
| Ceftriaxone                                             | 淋病；肺炎鏈球菌腦膜炎；草綠色鏈球菌心內膜炎；沙門氏菌病和傷寒；由非*Pseudomonas aeruginosa*引起的院內感染                                                                                                                                                                                                                                                                                                                                   | _S. pneumoniae_ (91% meningitis; 99% nonmeningitis); _E. coli_ (90%); _Klebsiella pneumoniae_ (88%)                                                                                                             |  
| Ceftazidime, cefepime                                   | 由兼性革蘭氏陰性桿菌和 *Pseudomonas* spp. 引起的院內感染                                                                                                                                                                                                                                                                                                                                                              | _P. aeruginosa_ (86%)                                                                                                                                                                                           |  
| Ceftaroline                                             | *S. pneumoniae*, MSSA, *H. influenzae, K. pneumoniae, Klebsiella oxytoca, E. coli*引起的CAP；由 MSSA, MRSA, *Streptococcus pyogenes, Streptococcus agalactiae, E. coli, K. pneumoniae, K. oxytoca* 引起的急性細菌性皮膚及皮膚結構感染                                                                                                                                                                                     | 大多數對 Ceftaroline 敏感；來自單一希臘醫院的四株 MRSA 分離株對 Ceftaroline 的 MIC >4 μg/mL[^c]；其他個案報告，包括在未曾接觸 ceftaroline 的患者[^d,e]                                                                                                   |  
| Ceftazidime-avibactam, meropenem-vaborbactam            | 由抗藥性革蘭氏陰性菌（包括 *Pseudomonas* 和一些厭氧菌）引起的複雜性尿路感染和複雜性腹腔內感染（ceftazidime-avibactam 與 metronidazole 併用）                                                                                                                                                                                                                                                                                                    | _P. aeruginosa_ (84–97%)[^f]<br><br>MDR Enterobacterales, including carbapenem-resistant Enterobacterales that produce KPCs<br><br>No activity against metallo-β-lactamases (e.g., NDM)                         |  
| Imipenem, meropenem                                     | 由 *Enterobacter* spp. 和產生 ESBL 的革蘭氏陰性桿菌引起的腹腔內感染                                                                                                                                                                                                                                                                                                                                                     | _P. aeruginosa_ (84%); _Acinetobacter calcoaceticus-baumannii_ complex (85%) (meropenem susceptibilities reported)                                                                                              |  
| Ertapenem                                               | CAP；複雜性尿路感染，包括腎盂腎炎；急性骨盆感染；複雜性腹腔內感染；複雜性皮膚和皮膚結構感染，不包括伴有骨髓炎或由 *P. aeruginosa* 引起的糖尿病足感染                                                                                                                                                                                                                                                                                                                | _Enterobacter cloacae_ (90%); _K. pneumoniae_ (98%)                                                                                                                                                             |  
| Aztreonam                                               | 對penicillin過敏患者由兼性革蘭氏陰性桿菌和 *Pseudomonas* 引起的感染                                                                                                                                                                                                                                                                                                                                                      | _P. aeruginosa_ (69%)                                                                                                                                                                                           |  
| Vancomycin                                              | 由 MRSA 引起的菌血症、心內膜炎和其他侵襲性疾病；肺炎鏈球菌腦膜炎；口服製劑用於 CDAD                                                                                                                                                                                                                                                                                                                                                     | _S. aureus_ (100%); _E. faecalis_ (96%); _E. faecium_ (34%)                                                                                                                                                     |  
| Daptomycin                                              | VRE 感染；MRSA 菌血症                                                                                                                                                                                                                                                                                                                                                                                     | _E. faecalis_ (99.9%)[^i]; _E. faecium_ (99.7%)[^i]; _S. aureus_ (99.9%)[^g]                                                                                                                                    |  
| Gentamicin, amikacin, streptomycin, tobramycin          | 與penicillin併用治療葡萄球菌、腸球菌或鏈球菌心內膜炎；與 β-lactam類併用治療革蘭氏陰性菌血症；腎盂腎炎                                                                                                                                                                                                                                                                                                                                        | _E. coli_ (gentamicin, 91%); _P. aeruginosa_ (amikacin, 82%; gentamicin, 84%); _A. calcoaceticus-baumannii_ complex (gentamicin, 89%)                                                                           |  
| Azithromycin, clarithromycin, erythromycin              | _Legionella, Campylobacter_, _Mycoplasma_ 感染；CAP；對penicillin過敏患者的A型鏈球菌咽喉炎；細菌性血管瘤病；*Helicobacter pylori*；鳥型分枝桿菌感染                                                                                                                                                                                                                                                                                    | _S. pneumoniae_ (60%); group A streptococci (82%); _H. pylori_ (75%)j                                                                                                                                           |  
| Clindamycin                                             | 嚴重、侵襲性的A型鏈球菌感染（與 β-lactam合用）；由絕對厭氧菌引起的感染；由敏感的葡萄球菌引起的感染                                                                                                                                                                                                                                                                                                                                              | _S. aureus_ (70%)                                                                                                                                                                                               |  
| Doxycycline, minocycline                                | 慢性支氣管炎的急性細菌性加重；輕度CAP；MRSA皮膚和軟組織感染；_Vibrio vulnificus_ 感染；披衣菌 (doxycycline)；Rickettsia感染（恙蟲病、斑疹傷寒）；penicillin過敏者治療放線菌感染；**鉤端螺旋體感染；梅毒；類鼻疽**；鼻疽；鼠疫；布魯氏菌病（與streptomycin合用）；兔熱病；萊姆病 (doxycycline)；腹股溝肉芽腫<br><br> ***Stenotrophomonas, Mycobacterium marinum***感染 (minocycline)<br>==健保給付僅限對CRAB==                                                                                                        | _S. pneumoniae_ (63%); _S. aureus_ (97%)                                                                                                                                                                        |  
| Tigecycline                                             | 由 _S. pneumoniae, H. influenzae_, or _Legionella pneumophila_ 引起的CAP；由 _E. coli_, vancomycin-susceptible _E. faecalis, Citrobacter freundii, E. cloacae, K. pneumoniae, K. oxytoca, Bacteroides_ spp., _Clostridium perfringens_, and _Peptostreptococcus_ spp.多重抗藥革蘭氏陰性菌和厭氧菌引起的複雜性腹腔內感染；由 _E. coli_, MRSA, MSSA, _S. pyogenes, Streptococcus anginosus, S. agalactiae, B. fragilis_ 引起的複雜性皮膚和軟組織感染 | Mostly susceptible, although case reports of resistance in _A. baumannii_ and _K. pneumoniae_                                                                                                                   |  
| TMP-SMX                                                 | 社區性UTI和社區性MRSA皮膚和軟組織感染                                                                                                                                                                                                                                                                                                                                                                              | _E. coli_ (73%); _S. aureus_ (95%)                                                                                                                                                                              |  
| Ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin | CAP (levofloxacin and moxifloxacin); UTI; _Pseudomonas_ infections (ciprofloxacin and levofloxacin)；醫院獲得性革蘭氏陰性腸道感染；細菌性腸胃炎                                                                                                                                                                                                                                                                           | _S. pneumoniae_ (99% levofloxacin); _E. coli_ (79% for ciprofloxacin and levofloxacin); _P. aeruginosa_ (ciprofloxacin, 76%; levofloxacin, 70%); **_Salmonella_ spp.** (72% for ciprofloxacin and levofloxacin) |  
| Rifampin                                                | **葡萄球菌異物感染（與其他抗葡萄球菌藥物聯合使用）; _Legionella_ pneumonia**; _Mycobacterium tuberculosis_; atypical nontuberculous mycobacterial infection                                                                                                                                                                                                                                                                 | _S. aureus_ (99%), although staphylococci rapidly develop resistance with monotherapy                                                                                                                           |  
| Metronidazole                                           | 絕對厭氧革蘭氏陰性菌（如 Bacteroides spp.）；肺、腦或腹部膿瘍；細菌性陰道炎；CDAD                                                                                                                                                                                                                                                                                                                                                 | Mostly susceptible; resistance very rare                                                                                                                                                                        |  
| Linezolid, tedizolid                                    | VRE; 由 MSSA 和 MRSA 引起的皮膚及軟組織感染；伴有菌血症的CAP；HAP                                                                                                                                                                                                                                                                                                                                                        | Mostly susceptible; resistance occasionally seen in VRE                                                                                                                                                         |  
| Colistin                                                | 由對其他所有治療方案耐藥的革蘭氏陰性桿菌引起的感染 (如 _P. aeruginosa, Acinetobacter_ spp., and _Stenotrophomonas maltophilia_)                                                                                                                                                                                                                                                                                               | _P. aeruginosa_ (case reports, outbreaks)                                                                                                                                                                       |  
| Nitrofurantoin                                          | 大多數革蘭氏陰性桿菌和一些革蘭氏陽性菌引起的UTI；反復性膀胱炎的預防                                                                                                                                                                                                                                                                                                                                                                 | _E. coli_ (95%); _E. faecalis_ (99%)                                                                                                                                                                            |  
| Fosfomycin                                              | 大多數革蘭氏陰性桿菌和一些革蘭氏陽性菌引起的尿路感染；反復性膀胱炎的預防                                                                                                                                                                                                                                                                                                                                                                | 被認為是低抗藥性                                                                                                                                                                                                        |  
| Cefiderocol                                             | 由多重抗藥革蘭氏陰性菌引起的複雜性尿路感染和/或腎盂腎炎，包括產生ESBL或carbapenemase的細菌以及多重抗藥性*Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Burkholderia cepacia complex*                                                                                                                                                                                                                          | 初步研究中顯示抗藥機率非常低                                                                                                                                                                                                  |  
  
## 本院有的抗生素  
### Cephalosporins  
第一代：Cefazolin, cephalexin (PO)  
第二代：Cefuroxime (IV, PO)  
第三代：Ceftriaxone, ceftazidime, cefoperazone/sulbactam, ceftazidime/avibactam, cefixime (PO)  
第四代：Cefepime  
第五代：Ceftaroline  
### Penicillins  
Penicillin G, penicillin benzathine (IM)  
Oxacillin, dicloxacillin (PO)  
Ampicillin, ampicillin/sulbactam  
Amoxicillin, amoxicillin/clavulanic acid (PO)  
Piperacillin, piperacillin/tazobactam  
### Carbapenems  
Ertapenem, imipenem/cilastatin, meropenem  
### Aminoglycosides  
Gentamicin, amikacin  
### Fluoroquinolones  
Moxifloxacin, ciprofloxacin, levofloxacin (IV, PO)  
### Tetracyclines  
Tetracycline (PO), doxycycline (PO), tigecycline, minocycline  
### Macrolides  
Azithromycin (PO), clarithromycin (PO), erythromycin  
### Glycopeptides, lipoglycopeptides, daptomycin, oxazolidinones  
Vancomycin, teicoplanin, daptomycin, linezolid (IV, PO)  
### Other anti-bacterials  
Clindamycin (PO)  
Fosfomycin (IV, PO)  
Trimethoprim-sulfamethoxazole (PO)  
Colistin  
Metronidazole (IV, PO)  
Rifampin, isoniazid, ethambutol, pyrazinamide (PO)  
### Anti-fungals  
Fluconazole (IV, PO): 對*Aspergillus spp., Candida krusei*無效; *Candida glabrata, Candida tropicalis*也可能沒效  
Voriconazole (IV, PO)  
Isavuconazole  
Anidulafungin  
Amphotericin B liposome  
  
## 孕婦  
  
- 不建議使用aminoglycosides, tetracyclines  
- Metronidazole, trimethoprim-sulfamethoxazole第一孕期禁用  
  
## 常見副作用  
  
### Ampicillin/sulbactam  
- 腹瀉  
- 偽膜性腸炎  
### Piperacillin/tazobactam  
- 腎毒性  
- 腸道菌群失衡（可能導致偽膜性腸炎）  
- 血小板減少症  
### Ceftriaxone   
- 肝毒性、黃疸  
- 不可加入含鈣之點滴注射液  
### **Cefepime**  
 - 神經毒性（尤其是在腎功能受損的病人中，可能引起癲癇）  
### Carbapenems  
 - 神經毒性（特別是在高劑量或腎功能不全時）  
### Aminoglycosides (Gentamicin)  
- 腎毒性：preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration  
- 耳毒性（可能引起聽力損失或平衡障礙）：proportional to the amount of drug given and the duration of treatment; tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage  
- 神經肌肉阻礙、呼吸衰竭  
### Sulfamethoxazole/Trimethoprim (TMP-SMX)  
- 高血鉀  
- 腎毒性  
- 肝毒性  
- 過敏反應  
- 骨髓抑制（可能引起貧血、白血球減少、血小板減少）  
### Vancomycin  
- 腎毒性  
- 耳毒性  
- 嗜中性球低下、白血球減少、血小板減少  
- ==**Red man syndrome**==：與vancomycin的劑量有所關聯，特別是發生在劑量較大且快速滴注時。主要是由皮膚、肺、腸胃道、心肌及血管系統中的**肥大細胞**及嗜鹼性白血球釋出**組織胺**所導致的。此現象通常發生在首次的給予劑量，但也可能會發生在任何一個給藥時間。一般常見的典型的症狀為**上半身軀幹**有潮紅、紅疹、蕁麻疹及搔癢之現象，在幾個比較嚴重的案例中曾發現低血壓、胸痛及呼吸窘迫之症狀。  
- 全身性過敏反應：是一種急性且危及生命的免疫反應，一般發生非常迅速，通常在給藥後之5-30分鐘以內發作。首先病人會對vancomycin敏感而在體內產生vancomycin特異性的IgE（vancomycin-specific IgE）。若對產生過敏之病人重複投予vancomycin會造成敏感性肥大細胞上的IgE接受器產生交叉連結反應，而引起血管活化調節物質的釋出，這些物質例如有組織胺、白三稀素C4（leukotriene C4）、前列腺素（prostaglandin D2）及細胞介質素，例如：腫瘤壞死因子（TNF-a）及interleukin 4, 5, 6, 7, 8及13。因為這些物質之釋出而擴大vancomycin之過敏反應進而產生血管擴張作用引起全身性皮膚紅疹、搔癢、蕁麻疹、支氣管收縮、腸道過度蠕動、低血壓或心律不整。  
### Daptomycin  
- 肌肉病變（myopathy）  
- Drug-induced eosinophilic pneumonia（少見）  
- Do not use for primary pneumonia: inactivated by pulmonary surfactant  
### Linezolid  
- 肝毒性  
- 血球低下（使用兩周以上）  
- 不可與單胺氧化酶抑制劑(monoamine oxidase inhibitor)或selective serotonin re-uptake inhibitor共同使用（serotonin syndrome）  
- 視神經病變  
- 乳酸中毒（少見）  
### Clindamycin  
- 腹瀉  
- 偽膜性腸炎（由困難梭狀桿菌引起）  
- 皮疹  
- 肝毒性  
### Tetracyclines (如doxycycline, minocycline)  
- 光感受性  
- 胃腸不適  
- 骨骼和牙齒發育障礙（特別是在兒童中）  
- 肝毒性  
- 併用Warfarin會加強Warfarin抗凝血功能增加出血的風險  
### Fluoroquinolones  
- QTc 延長  
- 肌腱炎及肌腱斷裂、關節病變（兒童不適合使用，老年人和同時用steroid的人使用fluoroquinolone會增加此副作用之風險）  
- 血糖異常（高血糖或低血糖）  
- 與aortic aneurysm or dissection可能有關  
### Macrolides   
- 胃腸道不適（如腹瀉、噁心）  
- QTc 延長  
- 肝毒性  
### Metronidazole  
- 腸胃不適（如噁心、嘔吐）  
- 周邊神經病變（長期使用）  
- 口腔金屬味  
- 酒精不耐受反應  
### Fluconazole  
- QTc 延長  
- 肝毒性  
### Amphotericin B  
- 腎毒性  
- 低血鉀  
- 輸注反應：發燒、寒顫、頭痛、心搏過速  
  
## 考古題  
### 專師  
  
  
### 內科醫師  
  
